CN Patent

CN101817813B — 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物

Assigned to Nanjing Cavendish Bio Engineering Technology Co Ltd · Expires 2013-04-10 · 13y expired

What this patent protects

本发明公开了一种3-(4-氨基-1-氧代-1，3-二氢-2H-异吲哚-2-基)哌啶-2，6-二酮的晶体IV，其X-射线衍射图，以度表示的2θ在7.7±0.2和11.9±0.2有衍射峰。此外，本发明还公开了该晶体的制备方法和药用组合物。

USPTO Abstract

本发明公开了一种3-(4-氨基-1-氧代-1，3-二氢-2H-异吲哚-2-基)哌啶-2，6-二酮的晶体IV，其X-射线衍射图，以度表示的2θ在7.7±0.2和11.9±0.2有衍射峰。此外，本发明还公开了该晶体的制备方法和药用组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN101817813B
Jurisdiction
CN
Classification
—
Expires
2013-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Cavendish Bio Engineering Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.